CRISPR Therapeutics (CRSP -0.92%) was a standout in the market last month as its shares charged 34% higher, according to data provided by S&P Global Market Intelligence. The biotech stock sustained its momentum from prior months with a strong quarterly report and encouraging news from regulators.CRISPR keeps the good news rollingThere wasn't any transformative news out of CRISPR Therapeutics last month. Instead, the company sustained the excitement generated by important regulatory approvals over the past f ...

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day. This rapid increase in functionality means the technology might become a powerful assistant for market research. For us at InvestorPlace, this sparks curiosity as to just how good of a tool AI chatbots are for collecting investing advice.So we decided to look into OpenAI’s ChatGPT stock predictions on the best biotech stocks for t ...

Just one day after the ascendant biotech CRISPR Therapeutics (CRSP -1.62%) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the stock to $112, suggesting that it could rise by 32% from its current price. The company is in the process of commercializing its first medicine, a gene therapy called Casgevy that it developed to treat beta thalassemia and sickle cell disease (SCD) as part of a collaboration with Vertex Pharmaceuticals. Casgevy was ...

Key Points CRISPR Therapeutics made worldwide headlines coming into 2024, receiving the first-ever FDA approval for a gene editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Next-gen gene editing will evolve Cas9 from molecular scissors to a molecular UPS truck delivering cargo to a specific part of the genome. CTX-211 is in Phase 1 clinical trials for treating Type 1 diabetes (T1D) with the goal of enabling patients to produce their insulin instead of relying on ...

CRISPR Therapeutics (CRSP) reported earnings of $1.10 per share for the fourth quarter of 2023 against the Zacks Consensus Estimate of a loss of 40 cents. In the year-ago period, the company had incurred a loss of $1.41 per share.The positive result was driven by collaboration revenue received from Vertex (VRTX) in connection with the approval of Casgevy (exagamglogene autotemcel [exa-cel]) for two blood disorder indications. Shares of CRSP rose 4.7% on Feb 21 as investors cheered the encouraging financial ...

Ole_CNXCRISPR Therapeutics (NASDAQ:CRSP), a leader in the gene-editing revolution, has captivated the attention of scientists and investors alike and received much attention from investors like Cathy Wood. Over the past five years, the company has been on a rollercoaster ride with explosive growth, going from a promising scientific tool to a reality with tangible therapeutic applications. Dramatic breakthroughs, regulatory approvals, and, of course, volatile price movements have marked this journey. So, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024 1:00 PM ET Company Participants Samarth Kulkarni - Chairman and Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citigroup Yigal Nochomovitz All right. Welcome back, everyone, to the next session of Citi's Virtual Oncology Leadership Summit. I'm Yigal Nochomovitz, one of the biotech analysts here at Citigroup. Remember if you have questions for Sam Kulkarni, the CEO of CRISP ...

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively – — Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively — — Clinical trial ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation rece ...

Cathie Wood's success is based on two main things: finding innovators and betting on them for the long term. The founder and chief executive officer of Ark Invest goes for innovators in all areas, from information technology to healthcare, and this helped her flagship Ark Innovation fund outperform the S&P 500 Index by a mile last year. Ark Innovation soared 67%, which the benchmark index advanced 24%.One of Wood's favorite technologies, in the area of healthcare, is gene editing, and last week, she increas ...